Idiopathic Membranous Nephropathy Clinical Trial
— MMF-STOP-IMNOfficial title:
A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy
Idiopathic membranous nephropathy (IMN) remains a common cause of the nephrotic syndrome in adults. There are few randomized clinical trials regarding the therapeutic effect of mycophenolate mofetil in patients with Idiopathic membranous nephropathy. This study aims to evaluate whether treatment with mycophenolate mofetil is non-inferior to cyclosporins in inducing long-term remission (complete or partial) of proteinuria in patients with idiopathic membranous nephropathy.
Status | Recruiting |
Enrollment | 128 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 1.Patients who provided informed consent - 2.Patients who are diagnosed as membranous nephropathy by renal biopsy,and other secondary factors are excluded - 3.18 years of age or older, male or female - 4.24 hours urine protein or spot urine protein/creatinine ratio > 8.0 g/day at least for twice confirmed - 5.The patients that satisfy more than three of following items are included even if proteinuria is less than 8 grams per day: 1. estimated glomerular filtration rate(eGFR) < 60 ml/min/1.73m2 2. Hypertension (BP above 140/90millimetre of mercury or BP above 120/80millimetre of mercury in patients taking anti-hypertensive agents) 3. 24 hours urine protein or spot urine protein/creatinine ratio > 5.0 g/day 4. Serum albumin (g/dL) < 3.0 Exclusion Criteria: - 1.Severe infective disease - 2.Allergy history to clinical trial medication and acute or chronic allergy for 4 weeks recently. - 3.Clinical history of treatment with other immunosuppressive medication - 4.Probability of pregnancy, breast feeding woman - 5.Uncontrolled hypertension (more than 160/100 millimetre of mercury ) - 6.estimated glomerular filtration rate(eGFR)<30 ml/min/1.73m2? - 7.Abnormal liver function test (more than 3 times above compared with normal value) - 8.Absolute neutrophil count <1,500/mm3 or leukocyte <2,500/mm3 or platelets <100,000/mm3 - 9.Secondary membranous nephropathy - 10.Expected life expectancy is less than 1 year - 11.The researchers evaluated that the patient's compliance was not appropriate for the trial - 12.Previous or present history of cancer and have risk of recurrence or metastasis |
Country | Name | City | State |
---|---|---|---|
China | Guangdong General Hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Guangdong General Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete Remission | Urinary protein excretion<0.3 g/d (uPCR<300 mg/g or <30 mg/mmol), confirmed by two values at least 1 week apart, accompanied by a normal serum albumin concentration, and a normal serum creatinine. | after treatment for 1 year. | |
Primary | Partial Remission | Urinary protein excretion <3.5 g/d (uPCR <3500 mg/g or <350 mg/mmol) and a 50% or greater reduction from peak values;confirmed by two values at least 1 week apart, accompanied by an improvement or normalization of the serum albumin concentration and stable serum creatinine. | after treatment for 1 year. | |
Secondary | estimated Glomerular Filtration Rate | time to a 50% reduction in baseline estimated Glomerular Filtration Rate (according to CKD-EPI) | after treatment for 1 year | |
Secondary | serum creatinine | time to doubling of baseline creatinine | after treatment for 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06245707 -
the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy
|
N/A | |
Recruiting |
NCT03864250 -
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy
|
N/A | |
Completed |
NCT01180036 -
MEmbranous Nephropathy Trial Of Rituximab
|
Phase 2/Phase 3 | |
Completed |
NCT01845688 -
Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy
|
N/A | |
Withdrawn |
NCT01093781 -
Aliskiren in Patients With Idiopathic Membranous Nephropathy
|
N/A | |
Completed |
NCT00362531 -
Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT05839314 -
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
|
Phase 4 | |
Completed |
NCT00302523 -
Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy
|
N/A | |
Terminated |
NCT03466801 -
The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.
|
N/A | |
Terminated |
NCT03475602 -
Membranous Nephropathy-associated Serological Antibody Predict the Prognosis of Idiopathic Membranous Nephropathy
|
||
Not yet recruiting |
NCT05850845 -
Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN
|
||
Not yet recruiting |
NCT05667883 -
Prognostic Model of GC/CTX in the Treatment of MN
|
||
Not yet recruiting |
NCT05667909 -
Prognostic Model of Rituximab in the Treatment of MN
|
||
Not yet recruiting |
NCT05667922 -
Prognostic Model of TAC in the Treatment of MN
|
||
Not yet recruiting |
NCT05667896 -
Prognostic Model of GC/TAC in the Treatment of MN
|
||
Recruiting |
NCT02173106 -
A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy
|
Phase 2 | |
Completed |
NCT01161459 -
Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid
|
N/A | |
Recruiting |
NCT03549663 -
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)
|
N/A | |
Not yet recruiting |
NCT05845762 -
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy
|
||
Completed |
NCT00694863 -
Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy
|
Phase 2 |